# The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma

Source: https://onco.cc/trials/nct07514533/  
OnCo record `nct07514533` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pucotenlimab in gallbladder cancer and other biliary tract cancers, run by Sir Run Run Shaw Hospital, not yet recruiting.

## Summary

The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma is a phase 2 interventional study registered as NCT07514533 by Sir Run Run Shaw Hospital, with a registry enrolment figure of 60 participants, started 2026-03-11 and due to reach its primary completion in 2027-12-31. Interventions recorded: Vibecototamab（iv）+Putilimab（iv）. Conditions listed: Cholangiocarcinoma. Gallbladder cancer is named in the registry entry: "* 1\) Age ≥ 18 years old, both male and female are acceptable. 2) Histologically confirmed unresectable or metastatic cholangiocarcinoma (including: gallbladder cancer, intrahepatic cholangiocarcinoma and extrahepatic ch". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07514533
- Phase: 2
- Setting: The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma
- Sponsor: Sir Run Run Shaw Hospital
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07514533: https://clinicaltrials.gov/study/NCT07514533

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Pucotenlimab](https://onco.cc/drugs/pucotenlimab/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07514533.json